Here are 11 highlights from the second edition of the contemporary art fair as well as some ongoing art exhibitions in ...

Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, VIM0423. This takes the company’s total funding ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A ...

VIMA taps into Cyprus as a place of confluence of identities and a multicultural node, but the fair’s founders are cautious about overtly calling it political. Photo: Daria Makurina The days of the ...

Though the current season has a rich cultural agenda and plenty of festive events, some organisers are already planning for 2026. The second edition of VIMA Art Fair is set to take place between May ...

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / July 10, 2020 / Binovi Technologies Corp., (formerly Eyecarrot Innovations Corp) (Binovi) (TSX-V:VISN)(OTCQB:EYCCF), a leader in neuro-vision performance ...

When Vima Therapeutics launched last year to take its drug candidate into human testing, the lead indication was isolated dystonia, a neurological movement disorder whose few treatment options leave a ...

Vima, the first international contemporary art fair in Cyprus, was a thrilling experience for the island and visiting collectors, curators and art lovers alike, both for the edgy location in a former ...

Add Yahoo as a preferred source to see more of our stories on Google. The second edition of Vima built on the momentum of the successful inaugural art fair in 2025, with more visitors (5,200) and ...

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...